Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

INFINITI

07/21/21 12:07 PM

Post #14

Is this trading or what ???

INFINITI

07/21/21 11:51 AM

Post #13

What’s going on here bought @.186 but it’s @.14

makinezmoney

01/07/20 9:20 AM

Post #12

Re: #11: @MWM - Are these exercisable at $6.50? They will be

$APOPW: L2 looks pretty silly right now

PreMarket Fun action...........

GO $APOPW

MWM

01/07/20 8:38 AM

Post #11

Re: #10: @makinezmoney - $APOPW: $APOP flying this morning on positive NEWS

Are these exercisable at $6.50? They will be looking good at the open!

https://www.sec.gov/Archives/edgar/data/1671502/000114420416115454/v445455_424b4.htm

makinezmoney

01/07/20 7:46 AM

Post #10

$APOPW: $APOP flying this morning on positive NEWS

Warrants should follow suit.

Currenty at $0.09

Should easily get to $0.35

Same as Feb-19 levels.

GO $APOPW

02opida

07/20/19 2:48 PM

Post #9

Cellect Biotechnology

midastouch017

06/14/17 7:39 AM

Post #8

Following the US, Cellect Receives Russian Patent Covering Any Device and Method Using Cellect's Flagship Technology - the ApoGraft™

TEL AVIV, Israel, June 14, 2017 /PRNewswire/ --

PATENT COVERS FIRST-IN-KIND DEVICES FOR SIMPLE AND ROBUST STEM CELL SELECTION REPLACING HIGH-COST AND COMPLEX PROCESSES USED TODAY

Dr. Shai Yarkoni, CEO, commented, "Russia is an multi-billion dollar market opportunity for Cellect's technology licenses."

Cellect Biotechnology Ltd. (Nasdaq: APOP, TASE: APOP), a developer of stem cells selection technology, announced today that further to the notices of allowance received from the US patent office, the Company has received further confirmation for grant of its patent by the Russian patent authorities (Application No. 2014138001) for a key composition of matter and method of use covering various devices using the ApoGraft for selection of Stem Cells.

Dr. Shai Yarkoni, CEO, commented, "Russia is an important market for us that we believe represents a multi-billion dollar market opportunity for Cellect's technology licenses. This patent is a fundamental base for the future commercialization of our global business and with the US already covered, Russia is the major next country to address. We are aware of the vast stem cell treatment performed nowadays in Russia and therefore believe that our technology will be well-suited this fast-growing demand for stem cells. Cellect has seven families of patents and patent applications to protect its core assets for enabling stem cell regenerative medicine. With this patent, Cellect we believe that has the opportunity to diversify its pipeline and open up new commercialization routes for additional market segments."

The device is designed to enable cell selection in a simplified setting by an off-the-shelf product - a solution that currently does not exist and that could potentially cover a wide range of unmet medical needs.

The devices covered by the patent are essentially containers (a bag, column, tube, bottle, vial, flask or bioreactor) comprised of a biocompatible material and a biologically active apoptosis-inducing ligand immobilized to a surface in the inner side of the container. The device is adapted to cell selection of apoptosis-sensitive cells. Specifically, the patent gives the company full protection against any devices that make use of apoptosis for cell selection. It also protects the method for using the device.

Such devices, enable selection for stem-cells and immune cells which support engraftment and negative selection for immune cells which induce graft versus host disease (GvHD) out of a heterogeneous cell population.

About Cellect Biotechnology Ltd.

Cellect Biotechnology is traded on both the NASDAQ and Tel Aviv Stock Exchange (NASDAQ: "APOP", "APOPW", TASE: "APOP"). The Company has developed a breakthrough technology designed to select stem cells from any given tissue, a technology that aims to improve a variety of stem cell applications.

The Company's technology is intended to provide pharma companies, medical research centers and hospitals with tools designed to rapidly select stem cells in quantity and quality that will enable stem-cell related treatments and procedures. Cellect's technology is applicable to a wide variety of stem cell-related treatments in regenerative medicine. The Company's current clinical trials are aimed at the cancer treatment of bone marrow transplantations.